Regenxbio (RGNX) Profit After Tax (2014 - 2025)

Regenxbio's Profit After Tax history runs 12 years deep, the most recent figure standing at -$67.1 million for Q4 2025.

• On a quarterly basis, Profit After Tax fell 41.26% year-over-year to -$67.1 million in Q4 2025; TTM through Dec 2025 was -$193.8 million, a 12.21% increase from a year earlier, with the FY2025 full-year figure at -$193.8 million, up 13.24% from the prior year.
• Profit After Tax fell to -$67.1 million in Q4 2025 per RGNX's latest filing, from -$61.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at $294.0 million in Q4 2021 and bottomed at -$86.1 million in Q1 2022.
• The 5-year median for Profit After Tax is -$60.6 million (2023), against an average of -$41.5 million.
• Biggest YoY gain for Profit After Tax was 735.85% in 2021; the steepest drop was 764.37% in 2021.
• Year by year, Profit After Tax stood at $294.0 million in 2021, then plunged by 115.05% to -$44.2 million in 2022, then plunged by 60.18% to -$70.9 million in 2023, then soared by 32.99% to -$47.5 million in 2024, then plunged by 41.26% to -$67.1 million in 2025.
• Per Business Quant, the three latest RGNX Profit After Tax figures stand at -$67.1 million (Q4 2025), -$61.9 million (Q3 2025), and -$70.9 million (Q2 2025).